Loading stock data…
$0.90-0.13 (-12.61%)
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands.
Lunai Bioworks Inc. in the Healthcare sector is trading at $0.90 with a market capitalization of $10M. The stock is currently near its 52-week low of $0.88, remaining 72.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20,942 | $0 | $0 | $0 | $0 |
| Gross Profit | $20,942 | — | — | — | $0 |
| Operating Income | -$1.43M↑ | -$1.82M↑ | -$2.48M↑ | -$4.11M↑ | -$4.16M |
| Net Income | -$2.57M↓ | -$1.80M↓ | $2.82M↑ | -$126.73M↓ | $189,176 |
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developin...